Keratin

Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Mutation, Epidermolysis bullosa, Skin cancer, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Protein, Life expectancy, Deformity, Blister, European, Skin, Collagen, COMP, Infection, Sponsor, European Commission, Safety, Unit, Marketing, COL7A1, Medicine, Pharmaceutical industry

Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Key Points: 


Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Anthraquinones, Skin cancer, Epidermolysis bullosa, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Joint, Protein, Life expectancy, Deformity, Blister, Interleukin-1 family, Mouth, European, Skin, Collagen, COMP, Infection, Safety, European Commission, Pain, Osteoarthritis, Marketing, Swelling, FGK, Medicine, Pharmaceutical industry

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, September 14, 2023
Antigen, Idiopathic disease, Nidogen, Drug development, Idiopathic pulmonary fibrosis, NASH, Culture, E pluribus unum, MHC, Cancer, Proteomics, Cathepsin B, TIMP3, Chronic obstructive pulmonary disease, Asporin, Lung transplantation, Protein, Keratin, Patient, Fatty liver disease, Integrin, Artificial intelligence, Conditional sentence, HEPA, IPF, Pharmaceutical industry, Vaccine, Dietary supplement

EDISON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from patients with idiopathic pulmonary fibrosis (“IPF”).

Key Points: 
  • In this study, FibroFind Ltd. (Newcastle, UK) obtained diseased lung tissue from two individuals undergoing lung transplantation for end-stage IPF, a deadly fibrotic lung disease.
  • Precision cut lung slices (PCLuS) were made and individually incubated in culture with rencofilstat, nintedanib, pirfenidone, or combinations of the compounds for four days.
  • Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis.
  • Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

SUNATORIA Launches Three Nourishing Hair Masks for Damaged Hair

Retrieved on: 
Wednesday, January 18, 2023
Mask, Organic acid, Paraben, Sodium, Woman, Vitamin E, Sulfate, Amazon, Elasticity, Hair, Keratin, Cosmetics, Tanning (leather), Boris Gudz

Hair Care Line Offers Hydrolyzed Keratin, Moroccan Argan Oil, and Purple Pigments for Blonde and Bleached Hair

Key Points: 
  • New York, New York--(Newsfile Corp. - January 18, 2023) - SUNATORIA, a brand specializing in high-quality keratin hair care, has launched three nourishing hair masks to rejuvenate damaged hair.
  • With this mission in mind, founder Dmytro Gudz began selling three hair masks, led by the Premium Keratin Hair Mask.
  • The Premium Keratin Hair Mask is a nourishing and rejuvenating treatment specifically designed for dry, damaged hair.
  • SUNATORIA also offers two other hair masks: the Keratin and Argan Oil Hair Mask and the Purple Keratin Hair Mask for blonde and bleached hair.

GK Hair Keratin Taming System: What To Expect?

Retrieved on: 
Thursday, August 25, 2022
Founder, And, CEO, Keratin, Industry, GK, Growth, Hair, Attention, Tanning (leather), Beauty salon

FORT LAUDERDALE, Fla., Aug. 25, 2022 /PRNewswire/ --The first ever product that GK Hair launched back in 2007 was a Keratin Taming Treatment.

Key Points: 
  • FORT LAUDERDALE, Fla., Aug. 25, 2022 /PRNewswire/ --The first ever product that GK Hair launched back in 2007 was a Keratin Taming Treatment.
  • Today, the company owns the production of an entire Hair Taming System along with five different variants of Juvexin-infused treatments.
  • As we introduced GK Hair's Taming Treatment , clients and salon professionals alike found a solution to common hair care concerns.
  • Today, the GK Hair Taming System has made its mark globally in the category of keratin smoothing treatments .

Nimbus Therapeutics Presents Clinical Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD Annual Meeting

Retrieved on: 
Friday, March 25, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, ClinicalTrials.gov, Therapy, Plaque, Microarray, Nimbus, AAD, Autoimmunity, American Academy of Dermatology, Skin, Program, Pathology, Patient, Psoriasis, Poster, Inflammation, Safety, RNA transfection, American College, TYK2, American Academy, Psoriasis Area and Severity Index, Cell proliferation, Keratin, Protein, Pharmaceutical industry, Medical imaging, NIMBUS THERAPEUTICS, THE NIMBUS TYK2 PROGRAM

Nimbus Therapeutics , a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today presented data from the Phase 1b clinical trial of its investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, in patients with moderate-to-severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • Nimbus Therapeutics , a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today presented data from the Phase 1b clinical trial of its investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, in patients with moderate-to-severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
  • As a Phase 1 study, the primary objective was evaluation of safety, and NDI-034858 was observed to be generally well tolerated.
  • The poster, titled Analysis of histologic, molecular and clinical improvement in moderate-to-severe psoriasis: Results from a Phase 1b trial of the novel allosteric TYK2 inhibitor NDI-034858, is on display through March 27, 2022.
  • Nimbus is conducting two clinical studies to evaluate its novel allosteric TYK2 inhibitor, including an ongoing moderate-to-severe plaque psoriasis (NCT04999839) study and the recently initiated active psoriatic arthritis (NCT05153148) study.

ProgenaCare Global announces effective applications of novel keratin matrix technology, ProgenaMatrix

Retrieved on: 
Wednesday, November 17, 2021
Patient, Skin, VII, Keratin, Industry, JG, Tissue engineering, Basement membrane, Doctor of Philosophy, Solution, Review, Collagen, type IV, alpha 1, View, CMS, Wound healing, Trauma, DPM, Keratinocyte, Multimedia, Silk, Tanning (leather), Medical device

The company's wound care technology, ProgenaMatrix, incorporates human keratin as a major component of the highly effective and affordable wound therapy.

Key Points: 
  • The company's wound care technology, ProgenaMatrix, incorporates human keratin as a major component of the highly effective and affordable wound therapy.
  • The human keratin technology in ProgenaMatrix is hydrated, non-cellular (not tissue-based), non-resorbing and supports the body's own healing process.
  • The bio-inspired design makes ProgenaMatrix the next generation of advanced wound therapy in the CMS skin substitute category.
  • Keratin technology has been in published literature for over a century with applications in wound healing, drug delivery, tissue engineering, trauma and medical devices.1 These studies inspired Progenacare to seek applications of keratin as a wound dressing.